Evaporative Dry Eye Clinical Trial
— MALTESEOfficial title:
Comparison of Tear Evaporation Rate With DAILIES TOTAL1 and Biotrue ONEday
NCT number | NCT04037969 |
Other study ID # | 41195 |
Secondary ID | |
Status | Completed |
Phase | N/A |
First received | |
Last updated | |
Start date | August 7, 2019 |
Est. completion date | November 26, 2019 |
Verified date | March 2021 |
Source | University of Waterloo |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of this pilot study is to compare the effect of DAILIES TOTAL1, a low water content silicone hydrogel lens, and Biotrue ONEday, a high water content hydrogel lens, on the rate of tear evaporation. The study will also serve to validate the novel, in-house developed evaporimeter.
Status | Completed |
Enrollment | 20 |
Est. completion date | November 26, 2019 |
Est. primary completion date | November 26, 2019 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 17 Years and older |
Eligibility | Inclusion Criteria: 1. Is at least 17 years of age and has full legal capacity to volunteer; 2. Has read and signed an information consent letter; 3. Is willing and able to follow instructions and maintain the appointment schedule; 4. Has worn soft contact lenses for a minimum of 6 months; 5. Currently wears soft contact lenses for at least 4 days per week and 8 hours per day; 6. Has an acceptable fit and comfort with both study contact lenses in the powers available; 7. Has less than or equal to 1.00DS difference between eyes in their habitual contact lenses; 8. Is willing to be awake for at least 2 hours before visit 2; 9. Is willing to not wear eye makeup on the day of visit 2 and 3; 10. Is willing to not use eye drops or artificial tears on the day of visits 1, 2, and 3; 11. Has a wearable pair of spectacles. Exclusion Criteria: 1. Is participating in any concurrent clinical or research study; 2. Has any known active* ocular disease and/or infection; 3. Has a systemic condition that in the opinion of the investigator may affect a study outcome variable; 4. Is using any systemic or topical medications that in the opinion of the investigator may affect a study outcome variable; 5. Has known sensitivity to sodium fluorescein dye; 6. Is pregnant, lactating or planning a pregnancy at the time of enrolment (by verbal confirmation at the screening visit); 7. Is aphakic; 8. Has undergone refractive error surgery; 9. Has a known sensitivity to petroleum jelly (Vaseline); 10. Has epilepsy and/or a sensitivity to flashing lights; 11. Wears toric contact lenses; 12. Has any physical impairment that would interfere with holding the evaporimeter; 13. Has taken part in another research study within the last 14 days. |
Country | Name | City | State |
---|---|---|---|
Canada | Centre for Ocular Research & Education | Waterloo | Ontario |
Lead Sponsor | Collaborator |
---|---|
University of Waterloo |
Canada,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Tear Evaporation Rate With Nesofilcon A | Tear film evaporation rate (% relative humidity per second) was performed using a novel evaporimeter as a non-invasive measurement of tear film evaporation. The slope was calculated from the change in humidity between 7 to 17.5 seconds while the eye was open and between 10 to 17.5 seconds when the eye was closed. Data from the both eyes were analyzed. | Baseline, 15 minutes post-contact lens, 6 hours post-contact lens | |
Primary | Tear Evaporation Rate With Delefilcon A | Tear film evaporation rate (% relative humidity per second) was performed using a novel evaporimeter as a non-invasive measurement of tear film evaporation. The slope was calculated from the change in humidity between 7 to 17.5 seconds while the eye was open and between 10 to 17.5 seconds when the eye was closed. Data from the both eyes were analyzed. | Baseline, 15 minutes post-contact lens, 6 hours post-contact lens |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT06176651 -
Evaluation of Miebo (Perfluorohexyloctane) Eyedrops in Habitual Contact Lens Wearers
|
Phase 4 | |
Completed |
NCT04091581 -
Comparison of Tear Evaporation Rate With Systane Complete in Dry Eye and Non-Dry Eye
|
Phase 4 | |
Active, not recruiting |
NCT04608942 -
Refractory Meibomian Gland Dysfunction and Plasma Jet
|
N/A | |
Completed |
NCT03055897 -
Tear Film Innovations iLux Safety Study
|
N/A | |
Completed |
NCT05536661 -
Impact of Tear Substitute Use on Dry Eye in Gamers.
|
N/A | |
Completed |
NCT04658927 -
Dextenza With ILUX for Treatment of MGD
|
Phase 4 | |
Not yet recruiting |
NCT04711642 -
Comprehensive Study on Dry Eye and Ocular Surface Disease Prior and After Cataract Surgery
|
Phase 3 | |
Completed |
NCT03055650 -
iLux Treatment for Meibomian Gland Dysfunction (MGD)
|
N/A | |
Not yet recruiting |
NCT06158997 -
Safety and Effectiveness of EyePeace on Signs and Symptoms of Dry Eye Disease
|
N/A | |
Completed |
NCT05331924 -
Quality of Life Improvement in Dry Eye Patients After Intense Pulsed Light Therapy Compared to Punctal Plugs
|
N/A |